Immunophenotypic clustering of myelodysplastic syndromes

Blood

Volumn 100, Issue 7, 2002, Pages 2349-2356

  Maynadié, Marc ^{a,b,c,d,e,f,g,h,i,j}   Picard, Françoise ^{a,b,c,d,e,f,g,h,i,j}   Husson, Bernard ^{a,b,c,d,e,f,g,h,i,j}   Chatelain, Bernard ^{a,b,c,d,e,f,g,h,i,j}   Cornet, Yvan ^{a,b,c,d,e,f,g,h,i,j}   Le Roux, Geneviève L ^{a,b,c,d,e,f,g,h,i,j}   Campos, Lydia ^{a,b,c,d,e,f,g,h,i,j}   Dromelet, Alex ^{a,b,c,d,e,f,g,h,i,j}   Lepelley, Pascalle ^{a,b,c,d,e,f,g,h,i,j}   Jouault, Hélène ^{a,b,c,d,e,f,g,h,i,j}   Imbert, Michèle ^{a,b,c,d,e,f,g,h,i,j}   Rosenwadj, Michelle ^{a,b,c,d,e,f,g,h,i,j}   Vergé, Véronique ^{a,b,c,d,e,f,g,h,i,j}   Bissières, Philippe ^{a,b,c,d,e,f,g,h,i,j}   Raphaël, Martine ^{a,b,c,d,e,f,g,h,i,j}   Béné, Marie Christine ^{a,b,c,d,e,f,g,h,i,j}   Feuillard, Jean ^{a,b,c,d,e,f,g,h,i,j}  

^a HÔPITAL DU BOCAGE   (France)

^b Hôpital Cochin AP HP ^*  (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d Hospital de Jolimont   (Belgium)

^e UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^f HÔPITAL NORD   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h HENRI MONDOR HOSPITAL   (France)

ⁱ UNIVERSITÉ DE LORRAINE   (France)

^j UNIVERSITÉ PARIS 13   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CD36 ANTIGEN; CD45 ANTIGEN; CD71 ANTIGEN;

ANEMIA; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL;

EID: 0036785306     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-01-0230     Document Type: Article

References (21)

1. Maynadié M, Verret C, Moskovtchenko P, et al. Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. Br J Cancer. 1996;74:288-290.
2. Sultan C, Imbert M, Jouault H, Scoazec JY. Myelodysplastic syndromes. Acta Haematol. 1987;78:91-93.
3. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.
4. Vallespi T, Imbert M, Mecucci C, Preudhomme C, Fenaux P. Diagnosis, classification, and cytogenetics of myelodysplastic syndromes. Haematologica. 1998;83:258-275.
5. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
6. Brunning RD, Bennett JM, Flandrin G, et al. Myelodysplastic syndromes. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:61-74.
7. Elghetany MT. Surface marker abnormalities in myelodysplastic syndromes. Haematologica. 1998;83:1104-1115.
8. Stetler-Stevenson M, Arthur DC, Jabbour N, et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood. 2001;98:979-987.
9. Elghetany T. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndromes [correspondence]. Blood. 2002;99:391.
10. Stetler-Stevenson M, Rick M, Arthur D. Diagnosis flow cytometric immunophenotyping in myelodysplastic syndrome: the US-Canadian consensus recommendations on the immunophenotypic analysis of hematological neoplasia by flow cytometry apply [correspondence]. Blood. 2002;99:391-392.
11. Lees O, Béné MC, GEIL Lmd. Immomarquages en cytométrie en flux. In: Lees O, Béné MC, eds. Immunophénotypage des leucocytes. Paris: Biotem Edition; 1998:405-451.
12. Lacombe F, Durrieu F, Briais A, et al. Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia. 1997;11:1878-1886.
13. Braytan RC, Orfao A, Borowitz MJ, Davis BH. Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting. Cytometry. 2001;46:23-27.
14. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998;95:14863-14868.
15. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
16. Chevillard S, Vielh P, Validire P, et al. French multicentric evaluation of MDR1 gene expression by RT-PCR in leukemia and solid tumours. Standardization of RT-PCR and preliminary comparisons between RT-PCR and immunohistochemistry in solid tumours. French Network of the Drug Resistance Intergroup, and Drug Resistance Network of Assistance Publique-Hopitaux de Paris. Leukemia. 1997;11:1095-1105.
17. Soligo DA, Oriani A, Annaloro C, et al. CD34 immunohistochemistry of bone marrow biopsies: prognostic significance in primary myelodysplastic syndromes. Am J Hematol. 1994;46:9-17.
18. Baur AS, Meuge-Moraw C, Schmidt PM, Padier V, Jotterand M, Delacretaz F. CD34/QBEND10 immunostaining in bone marrow biopsies: an additional parameter for the diagnosis and classification of myelodysplastic syndromes. Eur J Haematol. 2000;64:71-79.
19. Lash A, Saleem A. Iron metabolism and its regulation: a review. Ann Clin Lab Sci. 1995;25:20-30.
20. Lok CN, Loh TT. Regulation of transferrin function and expression: review and update. Biol Signals Recept. 1998;7:157-178.
21. Gattermann N. From sideroblastic anemia to the role of mitochondrial DNA mutations in myelodysplastic syndromes. Leuk Res. 2000;24:141-151.